What this desk is

What Peptides Foundation is

Peptides Foundation is an independent editorial desk focused on peptides with real clinical and preclinical data. It covers four compounds — tesamorelin, semaglutide, thymosin alpha-1, and PT-141 — not because they are the most widely used or the most talked-about, but because each has a published controlled-trial record that is meaningful enough to read carefully and report accurately.

This site is independent editorial commentary on publicly available research. It is not a store. It is not a clinic. It does not dispense medical advice, recommend doses, or facilitate access to any compound. The word 'Foundation' in the name refers to the research framework framing this desk — the idea of building understanding on solid clinical foundations — not to a registered nonprofit, charitable organization, or institutional body. No charitable status is claimed. There is no membership, no grant-making, and no organizational body behind this desk.

Editorial method

Sources used on this desk are restricted to: peer-reviewed journals (PubMed-indexed or equivalent); regulatory documents from the FDA and equivalent agencies; NIH-hosted monographs (LiverTox, DrugBank, ClinicalTrials.gov); and systematic reviews or meta-analyses of the above. Every factual claim is cited by number to a specific source listed in the references index.

The editorial voice applies a deliberate standard: lead with what is not established, flag single-lab or preclinical-only findings explicitly, note the study population when it limits generalizability (as with tesamorelin's HIV-specific trial base), and report null results with the same weight as positive ones (as with the 2025 TESTS sepsis trial for thymosin alpha-1 ^[13]). The goal is accuracy, not optimism.

Community-reported anecdotal effects are included on compound pages under a clear label — 'anecdotal, not clinical evidence' — because they are part of the real-world landscape around these compounds and ignoring them would be its own form of distortion. They are never presented as clinical findings.

Independence and limitations

This desk has no commercial relationship with any supplier, clinic, pharmaceutical company, or research organization covering the compounds described here. It does not carry advertising. It receives no industry funding.

Limitations to note: this desk is not a substitute for medical consultation. It does not assess individual health conditions, does not know the health history of any reader, and cannot determine whether any compound is safe or appropriate for a specific person. None of the four compounds on this desk should be approached without consulting a qualified clinician, particularly given that three of them are FDA-approved drugs requiring a prescription, and the fourth (thymosin alpha-1) is a non-US-approved compound available in the US only through investigational or compounding channels.

Content on this desk is updated as significant new evidence is published. The publication dates of cited studies are included in the references index so readers can assess currency.